Bolstering its news in January, when the firm disclosed that the intravenous antiplatelet cangrelor had proven strong in a Phase III trial as compared to oral clopidogrel, The Medicine Co.'s scientific team offered specifics over the weekend at the American College of Cardiology Scientific Session in San Francisco.